These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
803 related articles for article (PubMed ID: 31153385)
1. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385 [TBL] [Abstract][Full Text] [Related]
2. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759 [TBL] [Abstract][Full Text] [Related]
3. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report]. Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992 [TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma. Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041 [TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. Gambichler T; Strutzmann S; Tannapfel A; Susok L BMC Cancer; 2017 May; 17(1):327. PubMed ID: 28499411 [TBL] [Abstract][Full Text] [Related]
6. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Kosche C; Stout M; Sosman J; Lukas RV; Choi JN Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590 [TBL] [Abstract][Full Text] [Related]
7. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review. Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748 [TBL] [Abstract][Full Text] [Related]
9. A rare case of severe myositis as paraneoplastic syndrome on breast cancer. Dias LP; Faria AL; Scandiuzzi MM; Inhaia CL; Shida JY; Gebrim LH World J Surg Oncol; 2015 Apr; 13():134. PubMed ID: 25890160 [TBL] [Abstract][Full Text] [Related]
10. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy. Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777 [TBL] [Abstract][Full Text] [Related]
11. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Ohira J; Kawamoto M; Sugino Y; Kohara N Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733 [TBL] [Abstract][Full Text] [Related]
12. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725 [TBL] [Abstract][Full Text] [Related]
15. Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: a case report. Adi AH; Alturkmani H; Spock T; Williams Yohannes P; Wargo S; Szabo E; Gutkind JS; Van Waes C Head Neck; 2015 Jan; 37(1):E1-3. PubMed ID: 24715579 [TBL] [Abstract][Full Text] [Related]
16. [Dermatomyositis as a paraneoplastic syndrome]. Wennekers MM; Appelman M; van der Weele WF Ned Tijdschr Geneeskd; 2018; 161():D1916. PubMed ID: 29473536 [TBL] [Abstract][Full Text] [Related]
17. [Life-threatening flare of an underlying «paraneoplastic» dermatomyositis in a patient with lung adenocarcinoma treated with anti-PD-1 pembrolizuma]. Chauveheid F; von Frenckell C; Colin G; Deflandre E; Piette Y; Duysinx B; Bianchi E; Malaise M; Malaise O Rev Med Liege; 2022 Jul; 77(7-8):462-467. PubMed ID: 35924504 [TBL] [Abstract][Full Text] [Related]
18. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature. Messer A; Drozd B; Glitza IC; Lu H; Patel AB Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716 [TBL] [Abstract][Full Text] [Related]
19. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
20. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]